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Background
Energy sources fluctuate among carbohydrates, lipids, and amino acids depending on 
nutritional and metabolic status, such as feeding, fasting, and exercise. Under conditions 
of fasting, endurance exercise, malnutrition or metabolic disorders including diabetes 
Abstract 
We have developed a highly sensitive and specific method for quantification of salivary 
3-hydroxybutyrate (3HB), 3-hydroxyisobutyrate (3HIB), 3-hydroxy-3-methylbutyrate 
(3HMB) and 2-hydroxybutyrate (2HB), which could be new non-invasive biomarkers for 
catabolic pathways of fatty acids/ketogenic amino acids, valine, leucine, and methio-
nine/threonine/α-ketobutyrate, respectively. The four hydroxybutyrates (3HB, 3HIB, 
3HMB, and 2HB) were extracted from 5 µl of saliva, converted to 2-pyridylmethyl (2PM) 
ester derivatives, and measured by liquid chromatography–tandem mass spectrometry 
in positive electrospray ionization mode. [13C4]3HB was used as an internal standard. 
The detection limits for the 2PM esters were <1 pg (7.9–9.6 fmol) on-column (signal-
to-noise ratio = 3). Reproducibilities and recoveries of the hydroxybutyrates were 
validated according to one-way layout and polynomial equation, respectively. The vari-
ances between sample preparations and between measurements were calculated to 
be 0.45–5.28 and 0.54–3.45 %, respectively. Experiments performed using 5 µl of saliva 
spiked with 3.8–154.4 pmol of the four hydroxybutyrates gave recoveries of 98.5 to 
108.8 %, with a mean recovery of 104.1 %. In vitro experiments in hepatocytes or skele-
tal muscle cells showed that addition of palmitic acid, valine, leucine or α-ketobutyrate 
to culture medium markedly increased the targeted hydroxybutyrate concentrations. 
The salivary concentration of each targeted hydroxybutyrate was positively correlated 
with that in serum, and the salivary levels were elevated in patients with liver cirrho-
sis, which is characterized by upregulated catabolism of lipids and amino acids. The 
proposed method is useful for quantification of salivary 3HB, 3HIB, 3HMB, and 2HB for 
monitoring of catabolic activities of amino acids and fatty acids.
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mellitus (Gaster 2009; Adams et al. 2009) and chronic liver diseases (Syed et al. 2010), 
catabolism of fatty acids and amino acids in the liver and skeletal muscles is stimulated 
to compensate for the lack of glucose supply. Fatty acids are oxidized to acetyl-CoA in 
the mitochondrion (β-oxidation) and used in the TCA cycle, and excess acetyl-CoA in 
the liver is further metabolized to ketone bodies to supply energy to non-hepatic tissues, 
mainly brain and skeletal muscles (Fig. 1) (Laffel 1999). Amino acids are also an impor-
tant energy source under conditions lacking glucose, and ketone bodies could be pro-
duced from ketogenic amino acids in the liver in such metabolic status (Fig. 1). Because 
3-hydroxybutyrate (3HB) is the most stable ketone body in blood, serum 3HB concen-
tration reflects fatty acid β-oxidation as well as ketogenic amino acids catabolism in the 
liver (Robinson and Williamson 1980).
Fig. 1 Productive pathways of 3HB from fatty acids and ketogenic amino acids. Acyl-CoA derived from 
fatty acids is metabolized to Ac-CoA through β-oxidation pathway in the mitochondria. Ac-CoA in the liver 
is further metabolized to ketone bodies (acetoacetate, 3HB, and acetone) to supply energy to non-hepatic 
tissues when blood glucose level is low. Ketone bodies can be also metabolized from ketogenic amino acids, 
which are metabolized to intermediates in fatty acids β-oxidation, Ac-CoA or HMG-CoA via the respective 
catabolic pathway. 3HB is the most stable in blood among the ketone bodies. 3HB 3-hydroxybutyrate, 3HBDH 
3HB dehydrogenase, Ac-CoA acetyl-CoA, AcetoAc-CoA acetoacetyl-CoA, FFA fatty acids, HMG-CoA 3-hydroxy-
3-methylglutaryl-CoA, HMGCL HMG-CoA lyase, HMGCS HMG-CoA synthase, ILE isoleucine, Inner m. mitochon-
dria inner membrane, LEU leucine, LYS lysine, Outer m. mitochondrial outer membrane, Plasma m. plasma 
membrane, THR threonine, TRP tryptophan, TYR tyrosine
Page 3 of 18Miyazaki et al. SpringerPlus  (2015) 4:494 
In humans, branched-chain amino acids (BCAAs), valine (VAL), leucine (LEU) and 
isoleucine (ILE), are metabolized to succinyl-CoA or acetyl-CoA exclusively in skel-
etal muscle mitochondria and used in the TCA cycle (Shimomura et  al. 2006; Pla-
tell et al. 2000; Rennie et al. 2006; Kong et al. 2012). The first two steps of the BCAA 
metabolic pathways are conversion of BCAAs to their CoA-derivatives, catalyzed by 
common mitochondrial enzymes. The CoA-derivatives of BCAAs are finally metab-
olized to succinyl-CoA or acetyl-CoA by their own pathways, but CoA is released 
from 3-hydroxyisobutyryl-CoA only in the VAL catabolic pathway (Fig.  2). CoA-free 
Fig. 2 Productive pathways of 3HIB from VAL and 3HMB from LEU in BCAA metabolism. BCAAs are 
metabolized in the mitochondrion and the first two steps are catalyzed by common enzymes; first, BCAAs 
are deaminated to the respective BCKA by BCAT, and then the BCKAs are converted to the respective CoA-
derivatives by the BCKDH complex, which is the rate-limiting enzyme in BCAA catabolism. The respective 
CoA derivatives are finally metabolized to Ac-CoA and/or Suc-CoA. 3HIB is an intermediate of VAL catabolism 
that is released from 3HIB-CoA by HIBCH in the mitochondrion. The small molecule 3HIB leaks into extracel-
lular fluid. 3HMB is synthesized from KIC by KICDO in the cytoplasm as a BCKA derived from LEU. 3HMB is 
also detectable in extracellular fluid. 3HIB 3-hydroxyisobutyrate, 3HIB-CoA 3-hydroxyisobutyryl-CoA, α-Kg 
α-ketoglutaric acid, Ac-CoA acetyl-CoA, BCAA branched-chain amino acid, BCAT branched-chain aminotrans-
ferase, BCKA branched-chain α-keto acid, BCKDH complex BCKA dehydrogenase complex, GLU glutamate, 
KIC α-ketoisocaproic acid, KICDO KIC dioxygenase, KMV α-keto-β-methylvaleric acid, KIV α-ketoisovaleric acid, 
HIBCH 3HIB-CoA hydrolase, IB-CoA isobutyryl-CoA, ILE isoleucine, Inner m. mitochondria inner membrane, 
IV-CoA isovaleryl-CoA, LEU leucine, MB-CoA α-methylbutyryl-CoA, MC-CoA methacrylyl-CoA, MMS methyl-
malonate semialdehyde, Outer m. mitochondrial outer membrane, Plasma m. plasma membrane, PP-CoA 
propionyl-CoA, Suc-CoA succinyl-CoA, VAL valine
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3-hydroxyisobutyrate (3HIB) is then released from mitochondria into extracellular fluid 
(Letto et al. 1986). Therefore, 3HIB is a possible biomarker of VAL catabolism in skeletal 
muscle (Avogaro and Bier 1989). LEU is transaminated to α-ketoisocaproate (KIC) in the 
first step of the mitochondrial catabolic pathway, and approximately 5 % of KIC is trans-
ferred to cytoplasm and metabolized to 3-hydroxy-3-methylbutyrate (3HMB) by KIC 
dioxygenase (Fig. 2) (Sabourin and Bieber 1983). The synthesis of 3HMB is not directly 
associated with energy production (Zanchi et al. 2011), but this molecule can also pass 
through the plasma membrane and may be a biomarker for LEU catabolism in skeletal 
muscle.
In addition to production in the VAL and LEU catabolic pathways, succinyl-CoA is 
produced from α-ketobutyrate (αKB), which is generated when cysteine is synthesized 
from cystathionine by γ-cystathionase (CTH) in the methionine (MET) pathway or from 
threonine (THR) by serine/threonine dehydratase (SDH) (Fig. 3) (Stipanuk 2004; Green-
berg et al. 1967; Yang and Roth 1985). In this pathway, some cytoplasmic αKB is further 
reduced to 2-hydroxybutyrate (2HB) and this compound is released into extracellular 
fluid. It is uncertain if increased serum 2HB directly reflects upregulated catabolism of 
MET/THR, but metabolome analyses have shown that 2HB is a significant biomarker 
Fig. 3 Productive pathway of 2HB from αKB in the sulfur-containing amino acid metabolic pathway. 
Cystathionine, a metabolite of homocysteine, is metabolized to αKB and CYS. αKB is transported into the 
mitochondrion and converted to PP-CoA, a precursor of Suc-CoA, and is also reversibly converted to 2HB 
by 2HBDH. 2HB leaks into extracellular fluid. 2HB 2-hydroxybutyrate, 2HBDH 2HB dehydrogenase, αKB 
α-ketobutyrate, αKADH α-keto acid dehydrogenase, CYS cysteine, GSH glutathione, HCY homocysteine, Inner 
m. mitochondrial inner membrane, LDH lactate dehydrogenase, MET methionine, Outer m. mitochondrial 
outer membrane, PDH pyruvate dehydrogenase, Plasma m. plasma membrane, PP-CoA propionyl-CoA, SAM 
S-adenosyl methionine, SAH S-adenosyl homocysteine, SER serine, SDH serine/threonine dehydrase, Suc-CoA 
succinyl-CoA, THR threonine
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associated with early stage insulin resistance (Syed Ikmal et al. 2013; Gall et al. 2010; Fer-
rannini et al. 2013; Tripathy et al. 2015).
Non-invasive evaluation of metabolic status is increasingly important. Saliva has been 
used as a non-invasive sample in clinical examination, therapy and sport because it con-
tains various metabolites and can be self-collected easily and safely. Plasma 3HB, 3HIB 
and 3HMB are measured by gas chromatography–mass spectrometry (GC–MS) (Des 
Rosiers et al. 1988; Avogaro and Bier 1989; Nissen et al. 1990) and plasma 2HB, 3HB, 
and 3HMB by liquid chromatography–tandem mass spectrometry (LC–MS/MS) in neg-
ative electrospray ionization (N-ESI) mode (Deshpande et al. 2013; Sorensen et al. 2013; 
Gall et al. 2010; Ferrannini et al. 2013). However, these methods are not sufficiently sen-
sitive for measurement of 2HB, 3HB, and 3HMB in saliva. We have previously converted 
another organic acid, malonic acid, into a di-(1-methyl-3-piperidinyl)malonic acid deriv-
ative for measurement by LC–MS/MS in positive electrospray ionization (P-ESI) mode 
(Honda et al. 2009). The introduction of a tertiary amine moiety in malonate promoted 
protonation and markedly increased the sensitivity. Derivatization has also been used to 
quantify salivary 3HB (Tsutsui et al. 2012). In the current study, we converted salivary 
3HB, 3HIB, 3HMB, and 2HB into 2-pyridylmethyl (2PM) ester derivatives for simulta-
neous quantification using LC-P-ESI–MS/MS. In vivo and in vitro experiments showed 
that the levels of salivary 3HB, 3HIB, 3HMB, and 2HB reflect their serum concentra-
tions, which indicates that these molecules could be useful biomarkers for monitoring of 
catabolic pathways of amino acids and fatty acids.
Methods
Chemicals
Sodium 3HIB, sodium D-3HB, 3HMB, αKB, fenofibrate and fatty acid-free BSA were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Sodium DL-3HB-13C4 was 
obtained from Taiyo Nippon Sanso Co. (Tokyo, Japan) and sodium DL-2HB, 2-pyri-
dinemethanol and 2-methyl-6-nitrobenzoic anhydride were from Tokyo Kasei Kogyo 
(Tokyo, Japan). VAL, LEU, ILE, L-carnitine, palmitic acid and 4-dimethylaminopyridine 
were purchased from Wako Pure Chemical Industries (Osaka, Japan). Amino acid-free 
medium (Zero medium) was kindly supplied by Ajinomoto Pharmaceuticals Co., Ltd. 
(Tokyo, Japan). All other reagents for cell culture experiments were purchased from 
Thermo Fisher Scientific (Gibco®, Waltham, MA, USA). Solvents used for analysis were 
of analytical grade.
Sample collection
Saliva was collected from healthy volunteers (n = 15) and patients with liver cirrhosis 
(n = 22) by passive drool into a collection tube after mouth was washed out with water 
several times, and was immediately frozen at −20  °C until analysis. Blood and saliva 
were simultaneously collected from three healthy volunteers several times on different 
days to compare the concentrations of 3HB, 3HIB, 3HMB, and 2HB in saliva and serum. 
Blood samples were coagulated and centrifuged at 1500×g for 10 min, and serum was 
stored at −20 °C until analysis. In addition, to examine the influence of standing sam-
ple at room temperature (RT) on stability of four examined hydroxybutyrates, collected 
saliva samples from healthy volunteers (n =  4) were aliquoted into a microcentrifuge 
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tube (1.5 mL, Eppendorf, Hamburg, Germany) and kept in incubator set at 25 °C for 0, 1, 
2, 4, 6, 10, and 24 h, and then, transferred at −20 °C.
Informed consent was obtained from all subjects and the study protocol was approved 
by the Ethics Committee of Tokyo Medical University Ibaraki Medical Center (#12–34).
Sample preparation
Before analysis, saliva was thawed at RT and centrifuged at 3000×g for 15 min at 4 °C to 
remove denatured mucins and food particles (Tsutsui et al. 2012). Five µL of the super-
natant of saliva, serum, or culture medium was placed in the microcentrifuge tube, and 
769 pmol (100 ng) of sodium DL-3HB-13C4 in 100 μL of acetonitrile–water (19:1, v/v) 
was added as an internal standard. The sample tube was vortexed for 1 min and centri-
fuged at 2000×g for 1  min. After centrifugation, deproteinized clear liquid phase was 
collected and evaporated to dryness at 55  °C under a nitrogen stream. Conversion of 
3HB, 3HIB, 3HMB, and 2HB into 2PM ester derivatives was performed with some mod-
ifications of Shiina’s method for synthesis of carboxylic esters (Shiina et al. 2002). The 
reagent mixture consisted of 2-methyl-6-nitrobenzoic anhydride (67  mg), 4-dimethyl-
aminopyridine (20 mg), pyridine (900 μL) and 2-pyridinemethanol (100 μL). The freshly 
prepared reagent mixture (50 μL) was added to the sample extracts and the resulting 
mixture was allowed to stand at RT for 30 min. After addition of 1 mL of diethyl ether, 
the mixture was vortexed for 1 min and centrifuged at 700×g for 1 min. The clear super-
natant was collected and evaporated at 55  °C under nitrogen. The residue was redis-
solved in 100 μL of 1 % formic acid in water and centrifuged again at 700×g for 1 min. 
The supernatant was collected and a 2-µL aliquot was injected into the LC–MS/MS 
system.
Determination of 2PM‑3HB/3HIB/3HMB/2HB by LC‑P‑ESI–MS/MS
The LC–ESI–MS/MS system consisted of a TSQ Vantage triple stage quadrupole mass 
spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an HESI-II 
probe and a Prominence ultra-fast liquid chromatography (UFLC) system (Shimadzu, 
Kyoto, Japan). Chromatographic separation was performed using a Hypersil GOLD aQ 
column (150 × 2.1 mm, 3 μm, Thermo Fisher Scientific) at 40 °C. Initially, the mobile 
phase was acetonitrile–water (1:19, v/v) containing 0.2  % formic acid and was used 
at a flow rate of 300 µL/min for 5 min. After 5 min, the mobile phase was switched to 
0.2 % formic acid in acetonitrile at a flow rate of 300 μL/min for an additional 7 min. 
The general MS/MS conditions were as follows: spray voltage, 3000 V; vaporizer tem-
perature, 450 °C; sheath gas (nitrogen) pressure, 50 psi; auxiliary gas (nitrogen) flow, 15 
arbitrary units; ion transfer capillary temperature, 220 °C; collision gas (argon) pressure, 
1.0 mTorr; collision energy, 15 V; and ion polarity, positive; and selected reaction moni-
toring (SRM), m/z 196 → m/z 110 for 2PM-3HB, 2PM-3HIB and 2PM-2HB, m/z 210 → 
m/z 192 for 2PM-3HMB, and m/z 200 → m/z 110 for 2PM-[13C4]3HB.
Calibration curves
Stock solutions of sodium D-3HB (40 ng/20 μL), sodium 3HIB (40 ng/20 μL), 3HMB 
(40 ng/20 μL) and sodium DL-2HB (40 ng/20 μL) for construction of calibration curves 
were prepared in acetonitrile–water (19:1, v/v). These solutions were further diluted 
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with the same solvent to give a series of working standard solutions (1–200 ng/100 μL 
for 3HB, 0.1–40 ng/100 μL for 3HIB, 0.1–20 ng/100 μL for 3HMB and 2HB). Sodium 
DL-3HΒ-13C4 (100 ng) was added as an internal standard to each standard solution and 
the mixture was evaporated to dryness, derivatized and quantified, as described above.
Cell culture
Differentiated, nontransformed AML12 cells from transforming growth factor 
α-overexpressing transgenic mice (Wu et  al. 1994) (ATCC, Manassas, VA, USA) were 
used as a non-tumor mouse hepatocyte cell line. AML12 cells were cultured on a 24-well 
plate until confluent (Honda et  al. 2011a). For evaluation of hepatic β-oxidation, the 
growth medium was replaced by DMEM containing 1.0 g/L glucose, 1 mM l-carnitine 
and 200 µM palmitic acid dissolved in 10 % (w/v) fatty acid-free BSA with or without 
100  µM fenofibrate, a synthetic peroxisome proliferator-activated receptor α (PPARα) 
ligand. After 24 h, the 3HB level in the culture medium was measured. Confluent cells 
seeded on a 24-well plate were also exposed to 20 mM MET, cystathionine, THR or αKB 
in Zero medium containing 925 mg/L NaHCO3, 4.5 g/L glucose and 1 mM sodium pyru-
vate (Honda et al. 2011b) for 24 h. Serine (20 mM) was also added to the medium con-
taining MET. After exposure, the 2HB level in the culture medium was measured.
Growth of human primary skeletal muscle myoblasts isolated from the rectus abdomi-
nus muscle (ZenBio, Inc., NC, USA) and differentiation into myotubes were carried out 
on a 6-well plate following the recommended procedure of the manufacturer (ZenBio, 
Inc.). The differentiation medium was replaced by Zero medium containing 2 mM VAL, 
LEU or ILE (Honda et al. 2011b). 3HIB and 3HMB levels in the medium were measured 
after 24 h. All cells were incubated at 37  °C in a humidified incubator containing 5 % 
CO2 and 95 % air.
Statistics
The linearity of calibration curves was analyzed by simple linear regression. Reproduci-
bility was analyzed by one-way ANOVA. The estimated amount ± 95 % confidence limit 
was obtained as an index of precision (Taguchi 1986). To calculate these values, orthogo-
nal regression analysis was performed in a recovery study. The significance of differences 
between the results in different groups was evaluated by unpaired Student two-tailed t 
test or non-parametric Mann–Whitney U test. Data are reported as mean ± SEM. For 
all analyses, significance was accepted at P < 0.05. All statistical analyses were carried 
out using JMP software (SAS Institute Inc., Cary, NC, USA).
Results
MS, MS/MS and SRM
Typical P-ESI mass spectra for the 2PM esters of 3HB and 3HMB are shown in Fig. 4b, 
d. 2PM-3HB and 2PM-3HMB exhibited [M + H]+ ions at m/z 196 and m/z 210, respec-
tively, as the base peaks. In MS/MS spectra using these base peaks as precursor ions, 
the [C5H4NCH2OH +  H]+ ion was observed at m/z 110 as the most prominent peak 
(Fig. 4a, c). The [M-H2O + H]+ ion at m/z 192 was the second most prominent peak for 
2PM-3HMB (Fig. 4c). The mass spectra and MS/MS spectra for 2PM-3HIB and 2PM-
2HB were similar to those for 2PM-3HB. SRM chromatograms obtained for m/z 210 → 
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m/z 110 and m/z 210 → m/z 192 were compared for determination of 2PM-3HMB, and 
the latter showed a better signal-to-noise ratio (S/N) for biological samples. The detec-
tion limits of the 2PM esters of the four hydroxybutyrates by SRM were <1 pg (7.9–9.6 
fmol) on-column (S/N = 3).
Calibration curves
Calibration curves were established for 3HB, 3HIB, 3HMB and 2HB (Additional 
file  1: Fig.  S1). Different amounts of authentic hydroxybutyrates (0–200  ng for 3HB, 
0–40  ng for 3HIB, 0–20  ng for 3HMB and 2HB) were mixed with 100  ng (769  pmol) 
of [13C4]3HB as internal standard. The amount of each hydroxybutyrate and the peak-
area ratio to the internal standard measured by SRM were plotted on the abscissa and 
ordinate, respectively. Good linearity was found based on simple linear regression: 3HB: 
y = 0.0092x + 0.0020, n = 8, r2 = 0.9998, P < 0.0001; 3HIB: y = 0.0211x + 0.0032, n = 7, 
r2 = 0.9998, P < 0.0001; 3HMB: y = 0.0298x + 0.0043, n = 6, r2 = 0.9991, P < 0.0001; 
2HB: y = 0.0322x + 0.0038, n = 6, r2 = 0.9993, P < 0.0001.
Fig. 4 Typical P-ESI mass spectra (b, d) and product ion mass spectra (a, c) for 2PM-3HB (m/z 196) and 2PM-
3HMB (m/z 210). The mass spectra of 2PM-3HIB and 2PM-2HB were almost the same as 2PM-3HB. The LC–MS/
MS conditions are described in the “Methods”. P-ESI positive electrospray ionization, 2PM 2-pyridylmethyl. See 
legends of Figs. 1, 2, and 3 for other abbreviations
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Representative SRM chromatograms
Selected reaction monitoring chromatograms of 2PM esters of 3HB, 3HIB, 3HMB, 2HB 
and [13C4]3HB obtained with 5 μL of saliva from a healthy human subject are shown in 
Fig.  5. The peak-area ratio of each 2PM ester to 2PM-[13C4]3HB was calculated from 
the chromatograms and the amount was determined using this ratio on the calibration 
curve. The peaks for 2PM-3HB, 2PM-3HIB, 2PM-2HB and 2PM-3HMB on the chroma-
togram correspond to ~650 fmol (6.5 µM), ~350 fmol (3.5 µM), ~450 fmol (4.5 µM) and 
~70 fmol (0.7 µM), respectively.
Fig. 5 Representative SRM chromatograms of 2PM-derivatized 3HB, 2HIB, 3HMB, and 2HB in 5 µL of saliva 
from a healthy human. a m/z 196 g m/z 110 for 2PM-3HB, 2PM-3HIB and 2PM-2HB. b m/z 210 g m/z 192 for 
2PM-3HMB. c m/z 200 g m/z 110 for 2PM-[13C4]3HB. The peaks for 3HB, 3HIB, 2HB and 3HMB in chromato-
grams correspond to 650 fmol (6.5 µM), 350 fmol (3.5 µM), 450 fmol (4.5 µM) and 70 fmol (0.7 µM), respec-
tively. The numbers above the SRM ion pair represent the full scale of the chromatogram. SRM selected 
reaction monitoring; and see legends of Figs. 1, 2, 3, 4 for other abbreviations
Page 10 of 18Miyazaki et al. SpringerPlus  (2015) 4:494 
Precision and accuracy of the method
The following studies were performed to determine the precision and accuracy of the 
method using saliva from a healthy human subject. Reproducibility was investigated by 
analysis of quadruplicate samples by LC-P-ESI-SRM in triplicate (Table  1, Additional 
file 2: Tables S1, S2). The results were analyzed by one-way ANOVA, in which analyti-
cal errors were divided into two sources: sample preparation and SRM measurement. 
Variances were not considered to be attributable to the sample preparation because the 
errors during sample preparation were not significantly larger than those between the 
measurements. The inter-assay coefficients of variation for between- and within-sample 
variations of the four hydroxybutyrates were 0.45–5.28 and 0.54–3.45 %, respectively.
In recovery experiments, known amounts of each targeted hydroxybutyrate (a, 2a, 
3a; a = 51.2 pmol for 3HB, 50.0 pmol for 3HIB, 3.8 pmol for 3HMB, and 19.2 pmol for 
2HB) were spiked into 5-μL aliquots of saliva samples (n = 2). After clean-up and deri-
vatization, SRM was conducted in triplicate for each sample. The mean recoveries were 
103.7 % for 3HB (102.1–104.6 %), 99.6 % for 3HIB (98.5–100.7 %), 106.3 % for 3HMB 
(104.8–107.9 %), and 106.8 % for 2HB (108.7–118.8 %) (Table 2). The amount of each 
endogenous hydroxybutyrate found in unspiked 5-μL saliva aliquots was within the 95 % 
confidence limit for the respective estimated amount calculated by orthogonal regres-
sion analysis, which also constituted an index for the precision and accuracy of the 
method.
Cell culture experiments
3HB, 3HIB, 3HMB, and 2HB levels in culture medium were measured following treat-
ment of cells with different compounds. The level of 3HB, a possible marker of hepatic 
fatty acid β-oxidation, was significantly increased when hepatocytes were exposed to 
palmitic acid (Fig.  6a). Addition of fenofibrate with palmitic acid stimulated accumu-
lation of 3HB in the medium. Treatment of myotubes with VAL and LEU caused sig-
nificant elevation of the concentrations of 3HIB and 3HMB, respectively, in the medium 
compared with untreated myotubes or treatment with other BCAAs (Fig. 6b). Addition 
of other amino acids to the medium did not cause a significant change in the 3HIB or 
3HMB level in the culture medium (data not shown). In exposure of hepatocytes to αKB 
or its precursors (MET, THR or cystathionine), only αKB led to accumulation of 2HB in 
the medium (Fig. 6c).
Table 1 Reproducibility of the quantification of each hydroxybutyrate in human saliva
Each butyrate was quantified in 5 µL of saliva collected from healthy subjects. Four samples were prepared and quantified 
in triplicate by HPLC–MS/MS. The results were analyzed by a one‑way layout, in which the analytical errors were divided into 
two sources: sample preparation and SRM measurement
3HB 3‑hydroxybutyrate, 3HIB 3‑hydroxyisobutyrate, 3HMB 3‑hydroxy‑3‑methylbutyrate, 2HB 2‑hydroxybutyrate
Hydroxybutyrate Mean ± SD (n = 12) (pmol) Relative SD
Sample preparation (%) Error (SRM) (%)
3HB 56.0 ± 0.30 0.48 0.54
3HIB 49.0 ± 0.36 0.45 0.79
3HMB 3.7 ± 0.10 1.70 2.98
2HB 19.5 ± 0.84 5.28 3.45
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Human studies
Saliva collected from healthy volunteers was stood at RT (25 °C) for various times, and 
then, stored at −20 °C until analysis. After standing at RT, 3HB and 3HIB concentrations 
in saliva were unchanged for up to 24 h (Fig. 7). Similarly, 3HMB concentration in saliva 
was mostly kept for up to 24 h, although some variations were observed. On the other 
hand, 2HB concentration in saliva begun to decrease from an hour after standing at RT, 
Table 2 Recovery of each hydroxybutyrate from human saliva
Known amounts of each hydroxybutyrate were spiked into 5 µL of human saliva collected from healthy subjects before 
sample preparation
a Recovery (%) = (amount found − X¯0)/amount added × 100; X¯0 value was obtained from Table 1




3HB 51.2 103.4 ± 3.6 (6)
103.2 104.6 ± 1.6 (6)
154.4 102.1 ± 1.1 (6)
3HIB 50.0 98.5 ± 2.0 (6)
100.0 99.7 ± 1.0 (6)
150.0 100.7 ± 1.1 (6)
3HMB 3.8 104.8 ± 1.5 (6)
7.6 107.7 ± 0.6 (6)
11.4 107.9 ± 0.9 (6)
2HB 19.2 108.8 ± 5.4 (6)
38.4 118.8 ± 2.2 (6)
57.6 108.7 ± 2.5 (6)
Fig. 6 Concentrations of 3HB, 3HIB, 3HMB, and 2HB in cell culture media after addition of precursor com-
pounds. a AML12 cells were treated with 200 µM palmitic acid or 200 µM palmitic acid plus 100 µM fenofi-
brate for 24 h. 3HB concentrations were compared with that in untreated cells. b Myotubes were treated with 
2 mM VAL, LEU or ILE for 24 h. 3HIB and 3HMB concentrations were compared with those in untreated cells. 
c AML12 cells were treated with 2 mM MET plus SER, cystathionine, THR or αKB for 24 h, and 2HB concentra-
tions were compared among these conditions. Palmitic A palmitic acid. See legends of Figs. 1, 2, and 3 for 
other abbreviations. Data are from four independent experiments and are shown as mean ± SEM. Statisti-
cal analysis by one-way ANOVA multiple comparison and a post hoc Bonferroni multiple comparison test. 
†P < 0.001. All ANOVA P values were <0.0001
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and decreased significantly over one-third fold after four hours (Fig. 7). Therefore, saliva 
samples were stored at −20 °C immediately after collection in all other experiments.
Serum and saliva were collected from three healthy subjects repeatedly on different 
days. Significant correlations of the serum and saliva concentrations were found for all 
four hydroxybutyrates (3HB: r2 =  0.7034, P  <  0.0001; 3HIB: r2 =  0.6930, P  <  0.0001; 
3HMB: r2 = 0.2088, P < 0.05; and 2HB: r2 = 0.4599, P < 0.001) (Fig. 8). These results sug-
gest that the salivary levels reflect the serum levels of these examined hydroxybutyrates. 
The levels of 3HB, 3HIB, and 3HMB in saliva were significantly higher in patients with 
liver cirrhosis compared with healthy controls (Fig.  9); and that of 2HB tended to be 
higher in liver cirrhosis, but the difference was not significant.
Fig. 7 Influence of standing saliva samples at RT on stability of 3HB (a), 3HIB (b), 3HMB (c), and 2HB (d). Saliva 
samples collected from healthy volunteers (n = 4) were aliquoted into seven microcentrifuge tubes and 
standing at RT for various times (0, 1, 2, 4, 6, 10, and 24 h). Thereafter, the saliva samples were stored at −20 °C 
until analysis. RT room temperature. See legends of Figs. 1, 2, and 3 for other abbreviations. Data are shown as 
mean ± SEM. Statistical analysis by one-way ANOVA multiple comparison and a post hoc Dunnett’s multiple 
comparison test. ANOVA P values are a P = 0.9949, b P = 0.9968, c P = 0.7058, and d P < 0.0001. *P < 0.05, 
‡P < 0.0001 vs. 0-time control
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Discussion
We established a sensitive and specific new LC-P-ESI–MS/MS method for simultane-
ous quantification of four hydroxybutyrates (3HB, 3HIB, 3HMB, and 2HB) in human 
saliva, serum, and cell culture medium. Several methods for quantification of some 
hydroxybutyrates using LC-N-ESI–MS/MS have been developed (Deshpande et al. 2013; 
Sorensen et al. 2013). However, these methods have detection limits for 3HMB and 3HB 
of 0.3  µM (Deshpande et  al. 2013) and 3  µM (Sorensen et  al. 2013), respectively, and 
a >100-µL blood sample is required for quantification. The concentrations of the four 
examined hydroxybutyrates in saliva are 0.7–6.5 µM (Fig. 5) and quantification of these 
compounds in a small volume of saliva is difficult. Indeed, our preliminary study showed 
that only trace amounts of the four hydroxybutyrates in saliva were detected by LC-N-
ESI–MS/MS without derivatization.
Conversion of the four hydroxybutyrates into 2PM ester derivatives gave excellent 
peak shapes, [M + H]+ ions as base peaks in P-ESI–MS, and detection limits by SRM 
that were approximately 50 times lower than those for underivatized hydroxybutyrates 
in N-ESI mode (data not shown). Using this method, the four hydroxybutyrates in saliva 
Fig. 8 Correlation of 3HB, 3HIB, 3HMB, and 2HB concentrations between serum and saliva. a 3HB 3-hydroxy-
butyrate, y = 10.8x − 13.6 (r2 = 0.7034, P < 0.0001), b 3HIB 3-hydroxyisobutyrate, y = 15.4x − 1.2 (r2 = 0.6930, 
P < 0.0001), c 3HMB 3-hydroxy-3-methylbutyrate, y = 4.2x − 0.8 (r2 = 0.2088, P < 0.05), d 2HB 2-hydroxybu-
tyrate, y = 8.7x − 18.2 (r2 = 0.4599, P < 0.001)
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were easily quantified. Recently, Tsutsui et al. determined 3HB in human saliva by LC-P-
ESI–MS/MS after derivatizing with (S)(+)-1-(2-pyrrolidinylmethyl)-pyrrolidine (Tsutsui 
et al. 2012). This method is also sensitive and enantiomeric separation of d- and l-3HB 
was achieved. However, 3HIB, 3HMB, and 2HB that are derived from amino acids were 
not quantified and 100 µL of saliva was used. Our method requires only 5 µL of saliva 
and can be applied to determination of the four hydroxybutyrates in lachrymal fluid col-
lected with filter paper. Saliva and lachrymal fluid can be obtained non-invasively from 
humans and the concentrations of our four targeted hydroxybutyrates were significantly 
correlated among serum, saliva, and lachrymal fluid (data not shown). We chose saliva 
to monitor amino acids and lipid catabolic pathways because this can be more easily 
collected compared to lachrymal fluid. In addition, this high sensitive method can be 
applied to quantify the four hydroxybutyrates in other biological samples including 
serum, plasma, and urine that contain higher levels of them. Indeed, serum levels of 
3HB, 3HIB, 3HMB, and 2HB were quantified in the present study (Fig. 8). In saliva, 3HB, 
3HIB, and 3HMB concentrations were stabile at RT for at least 24 h (Fig. 7). However, 
2HB concentration in saliva was decreased soon in several hours by standing at RT. The 
reason is unclear why salivary 2HB is unstable at RT, but saliva sample needs to freeze 
immediately after collection until analysis.
Our cell culture experiments confirmed that the four targeted hydroxybutyrates are 
metabolites of lipid and amino acids; i.e. 3HB was synthesized by hepatic fatty acid 
β-oxidation, 3HIB and 3HMB by skeletal muscular BCAA catabolism, and 2HB in the 
MET/THR/αKB pathways. In low nutritional states such as fasting, metabolic disor-
ders and endurance exercise, 3HB serves as an excellent fuel for non-hepatic tissues 
and the serum level of 3HB is increased by stimulated hepatic β-oxidation as well as 
ketogenic amino acids catabolism (Laffel 1999). Elevation of serum 3HIB has also been 
found in fasted and diabetic subjects because BCAAs are utilized as another energy fuel 
in a low nutritional state (Avogaro and Bier 1989). The early steps in catabolism of the 
Fig. 9 Concentrations of 3HB, 3HIB, 3HMB, and 2HB in saliva from patients with liver cirrhosis and healthy 
controls. Data are expressed as mean ± SEM. Statistical analysis by unpaired Student t test or non-parametric 
Mann–Whitney U test. * P < 0.05, ** P < 0.01, ‡P < 0.0001. See legends of Figs. 1, 2, and 3 for abbreviations
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three BCAAs are thought to be concurrent reactions because the first two steps share 
the same enzymes: branched-chain aminotransferase and rate-limiting branched-chain 
α-keto acid dehydrogenase (BCKDH) complex (Shimomura et al. 2006). Therefore, the 
VAL metabolite 3HIB is thought to be a common biomarker for BCAA catabolism in 
skeletal muscle. Indeed, our data show that salivary levels of 3HB, 3HIB and 3HMB 
increased in parallel in patients with liver cirrhosis compared with those in healthy con-
trols. Liver cirrhosis causes an imbalance of whole body energy metabolism, including 
impaired glucose tolerance, ketoacidosis and insulin resistance (Moriwaki et al. 2004). 
In skeletal muscles, BCAAs are used for compensatory energy production, and conse-
quently protein breakdown and muscle atrophy develop in patients with liver cirrhosis 
(Shimomura et al. 2006; Platell et al. 2000; Moriwaki et al. 2004).
2HB is synthesized from αKB by a NADH-dependent 2-hydroxybutyrate dehydro-
genase (2HBDH) in cytosol, and αKB is metabolized to propionyl-CoA and then to 
succinyl-CoA in mitochondria. Therefore, an elevated 2HB concentration appears to 
reflect increased activity of 2HBDH and/or decreased mitochondrial metabolism of αKB 
(Fig. 3). 2HBDH is an isozyme of lactate dehydrogenase (LDH), and production of 2HB 
from αKB is analogous to that of lactate from pyruvate (Landaas and Pettersen 1975). 
Metabolism of αKB to propionyl-CoA in mitochondria is thought to be catalyzed by a 
specific NAD+-dependent αKB dehydrogenase complex or other α-keto acid dehydro-
genase complexes, including pyruvate dehydrogenase (PDH) and BCKDH (Linn et  al. 
1969b; Bremer 1969; Johnson and Connelly 1972). This activity is inhibited by phospho-
rylation of the E1 component of the complexes by enzymes such as pyruvate dehydroge-
nase kinase and BCKDH kinase (Kerbey et al. 1976). Gene expression of these kinases 
is upregulated by an elevated mitochondrial NADH/NAD ratio (Johnson and Connelly 
1972; Linn et al. 1969a; Bremer 1969). Thus, elevation of this ratio increases the cellu-
lar αKB concentration through inhibition of αKB and α-keto acid dehydrogenase com-
plexes, and an elevated cytosolic NADH/NAD ratio stimulates 2HB production through 
activation of 2HBDH.
αKB and pyruvate are structurally similar monocarboxylic keto acids and both are 
substrates of PDH; therefore, αKB may interfere with glucose metabolism by competi-
tive inhibition of PDH (Lapointe and Olson 1985; Bremer 1969). αKB also inhibits trans-
port of pyruvate into mitochondria (Paradies and Papa 1975). Brass showed that αKB 
significantly inhibited 14CO2 generation and [14C]glucose formation from [14C]pyruvate 
in rat hepatocytes, which implies that αKB reduces synthesis of acetyl-CoA and gluco-
neogenesis (Brass 1986). Early literature showed increased urinary and serum levels of 
2HB in patients with various clinical disorders combined with ketoacidosis and lactic 
acidosis (Landaas and Pettersen 1975), but more recent studies suggest that serum 2HB 
is a significant biomarker associated with insulin sensitivity, diabetes mellitus and car-
diovascular diseases (Syed Ikmal et al. 2013; Gall et al. 2010). In the current study, the 
salivary 2HB concentration in cirrhotic patients tended to be higher than that in healthy 
subjects. In cell culture, 2HB was produced by cultured hepatocytes when αKB, but not 
its precursors (MET, cystathionine or THR), was added. Therefore, increased 2HB levels 
in blood and saliva may reflect decreased mitochondrial metabolism of αKB, rather than 
increased catabolism of MET, cystathionine or THR. Serum 2HB might be an indicator 
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of insulin resistance because accumulation of αKB results in elevation of 2HB and dis-
turbance of mitochondrial pyruvate metabolism.
Conclusion
In this study, four hydroxybutyrates (3HB, 3HIB, 3HMB, and 2HB) were converted to 
2PM esters and measured by LC-P-ESI–MS/MS. This highly sensitive method made 
it possible to quantify concentrations of the four hydroxybutyrates in a small volume 
of human saliva, which can be conveniently used in place of serum. The four targeted 
hydroxybutyrates are intermediates in amino acid and fatty acid catabolic pathways that 
produce acetyl-CoA and succinyl-CoA in liver and skeletal muscles. Therefore, these 
four hydroxybutyrates are possible biomarkers for metabolic profiling of amino acids 
and lipids. This non-invasive method is applicable in clinical diagnosis, early detection 
of metabolic diseases, and evaluation of drug therapy; in nutritional support for patients 
and athletes; and in the anti-aging field.
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